Hepatology

Strnad explains the need for noninvasive biomarkers in AATD liver disease and early research about circulating Z-polymer’s potential association with clinically relevant adverse outcomes.

In this video segment, Reau, Trivedi, and Hirschfield discuss pipeline developments and other advances in primary biliary cholangitis they are most looking forward to.

In this video segment, Reau, Trivedi, and Hirschfield discuss how the emergence of second-generation PPAR agonists like seladelpar and elafibranor impact PBC management.

In this video segment, Reau, Trivedi, and Hirschfield discuss how treatment sequencing in PBC has evolved over time with the emergence of new second-line therapies and considerations for determining sequencing.

A new study found physical activity held more weight in the link between the joint exposure of sleep duration, metabolic equivalent of task, and Healthy Eating Index -2015 and MAFLD.

High-risk alcohol use was linked to greater rates of cirrhosis in patients with HCV but did not significantly impact rates of sustained virologic response.

Investigators highlight the need for tailored interventions to improve sleep disturbances and overall health in patients with hepatocellular carcinoma.

The accelerated approval is based on phase 3 data demonstrating seladelpar’s impact on ALP reduction and is contingent upon verification and description of clinical benefit in confirmatory trial(s).

Findings highlight a 78.4% treatment success rate among patients who prematurely discontinued DAAs, reaching 93.5% among those who discontinued after week 4.

Projections from an agent-based model based on data from Ontario, Canada, suggest both current and prospective strategies may not meet World Health Organization HCV goals.

Study finds elevated HAMD-17 scores in PBC patients predict cirrhosis risk, with depressive symptoms linked to higher liver enzyme levels and worse UDCA response.

Results suggest discordance between FIB-4 and liver stiffness measurement for MASLD-related fibrosis risk stratification.

Treatment with GLP-1 RAs led to improvements in weight loss, liver function tests, and liver fat in patients with diabetes and MASLD, with hepatic improvements independent of weight loss.

Use of illicitly manufactured fentanyl was linked to a 64% increased risk of acquiring hepatitis C infection among people who inject drugs.

Nearly one-third of eligible patients declined HIV/HCV testing, with notable sex-based differences observed among non-Hispanic Black patients.

New expert panel recommendations outline considerations for initiating and monitoring resmetirom treatment in patients with MASH and moderate fibrosis.

This July 2024 month in review highlights pipeline movement in hepatology as well as research about novel diagnostic/prognostic approaches and factors impacting hepatic health outcomes.

Findings support the safety and efficacy of using HBsAg-positive donor kidneys in HBsAg-negative recipients, noting a lack of impact on posttransplant outcomes.

Results showed significant reductions in mean HbA1c, fasting glucose, and insulin resistance in patients with chronic HCV infection and type 2 diabetes who achieved SVR with DAAs.

Greater circulating Z-polymer levels were associated with an increased risk of adverse clinical outcomes in adults with AATD and the PiZZ genotype.

Results suggest cholesterol absorption inhibitors are linked to a lower risk of liver cancer, but no association was observed for other nonstatins like fibrates, omega-3 fatty acids, and niacin.

Patients with MASH and cirrhosis had a greater prevalence of comorbidities and faced increased annual total health care costs compared to those without cirrhosis.

Findings suggest the current emphasis on targeting inflammation to mitigate fibrosis in MASLD may be incorrect, citing the minimal impact of LBP function loss on fibrosis.

Using NHANES data, researchers calculated AGILE 3 + and AGILE 4 scores to determine the prevalence of advanced fibrosis and cirrhosis in patients with MASLD in the US.

Positive topline results from the phase 2 SPRING trial highlight CM-101’s anti-fibrotic, anti-inflammatory, and anti-cholestatic effects in primary sclerosing cholangitis.